SOLTI Breast Cancer Research Group

• A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain

  Collaborator, Phase 3, Active, not recruiting, 101 people, 8 Jan 2025

• NCT05982093

  Phase 2, Recruiting, 96 people, 8 Aug 2023

• NCT05569811

  Phase 2, Active, not recruiting, 120 people, 6 Oct 2022

• Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)

  Collaborator, Phase 3, Recruiting, 220 people, 23 Aug 2022

• NCT05207709

  Phase 3, Terminated, 61 people, 26 Jan 2022

• NCT04130152

  Early phase 1, Completed, 22 people, 17 Oct 2019

• NCT04102618

  Collaborator, Early phase 1, Terminated, 26 people, 25 Sept 2019

• NCT04053322

  Collaborator, Phase 2, Active, not recruiting, 172 people, 12 Aug 2019

• NCT03609047

  Collaborator, Phase 2, Active, not recruiting, 366 people, 1 Aug 2018

• NCT03248427

  Phase 2, Completed, 106 people, 14 Aug 2017

• NCT02947685

  Collaborator, Phase 3, Active, not recruiting, 518 people, 28 Oct 2016

• NCT02802748

  Early phase 1, Completed, 60 people, 16 Jun 2016

• NCT02448420

  Phase 2, Completed, 73 people, 19 May 2015

• NCT02301988

  Collaborator, Phase 2, Completed, 151 people, 26 Nov 2014

• NCT02273973

  Collaborator, Phase 2, Completed, 334 people, 24 Oct 2014

• NCT01973660

  Phase 2, Completed, 151 people, 31 Oct 2013

• NCT01204125

  Collaborator, Phase 2, Completed, 141 people, 17 Sept 2010

• NCT00553358

  Collaborator, Phase 3, Completed, 455 people, 5 Nov 2007

Sources: clinicaltrials.gov